Fig. 7.

Neutrophil activation is not altered by prasugrel in the prodrug form. (A) CD16 surface expression was determined by flow cytometry following pre-exposure to prasugrel prodrug at a concentration of 5 μM for 2 minutes (n = 3, mean ± S.E.M.) following stimulation with either fMLP (10 μM) or PAF (10 nM). (B) Neutrophil transmigration was evaluated after fMLP-induced (10 μM) or PAF-induced (10 nM) activation (1 hour at 37°C) with cells incubated with prasugrel prodrug or negative control (Ctr) (n = 3, mean ± S.E.M.). (C) Platelet-neutrophil aggregate formation was evaluated in the presence of prasugrel prodrug (5 μM), following activation with fMLP (10 μM) or PAF (10 nM) (n = 3, mean ± S.E.M.).